Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Lowell Farms Inc. Announces Unaudited Second Quarter 2024 Financial and Operational Results
Posted: August 14, 2024 at 2:37 am
SALINAS, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California cannabis company with advanced distribution and production capabilities including extraction, manufacturing, sales and brand management, announces unaudited revenue and operating results for the second quarter of 2024 (ended June 30, 2024). All figures stated are in US Dollars.
The rest is here:
Lowell Farms Inc. Announces Unaudited Second Quarter 2024 Financial and Operational Results
Posted in Global News Feed
Comments Off on Lowell Farms Inc. Announces Unaudited Second Quarter 2024 Financial and Operational Results
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Posted: August 14, 2024 at 2:37 am
DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update.
Go here to see the original:
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Posted in Global News Feed
Comments Off on Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
Posted: August 14, 2024 at 2:37 am
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSEAM: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the second quarter ended June 30, 2024, and reviewed recent business highlights.
The rest is here:
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
Posted in Global News Feed
Comments Off on Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
Posted: August 14, 2024 at 2:37 am
This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three doses of NKX019 on Days 0, 7, and 14.
See the original post here:
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
Posted in Global News Feed
Comments Off on Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in…
Posted: August 14, 2024 at 2:37 am
INSIDE INFORMATION
See the original post:
Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in...
Posted in Global News Feed
Comments Off on Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in…
Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
Posted: August 14, 2024 at 2:36 am
See the original post:
Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
Posted in Global News Feed
Comments Off on Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
44,767 Orion Corporation A shares converted into B shares
Posted: August 14, 2024 at 2:36 am
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE14 AUGUST 2024 at 9.30 EEST
Follow this link:
44,767 Orion Corporation A shares converted into B shares
Posted in Global News Feed
Comments Off on 44,767 Orion Corporation A shares converted into B shares
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Posted: July 29, 2024 at 2:33 am
TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (A?) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD).1
Visit link:
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Posted in Global News Feed
Comments Off on Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
Genetic Technologies Strategic Restructure Driving USA Sales Growth
Posted: July 29, 2024 at 2:33 am
CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, has conducted an operations review and announces that it intends to transition to a capital light operations model – which is anticipated to result in an immediate material reduction in operating costs. This capital light operations model is intended to focus on sales growth (particularly in the Company's largest market in the United States) and move the Company's operations to an outsourced / collaborations approach (rather than the more expensive current in house laboratory operations).
More here:
Genetic Technologies Strategic Restructure Driving USA Sales Growth
Posted in Global News Feed
Comments Off on Genetic Technologies Strategic Restructure Driving USA Sales Growth
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
Posted: July 29, 2024 at 2:33 am
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) for Ipsen’s Iqirvo® (elafibranor) for the treatment of Primary Biliary Cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as a monotherapy in patients unable to tolerate UDCA.
Go here to read the rest:
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
Posted in Global News Feed
Comments Off on GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
